Page last updated: 2024-11-04

vorinostat and HIV

vorinostat has been researched along with HIV in 5 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.

Research Excerpts

ExcerptRelevanceReference
"Demethylation of H3K27 mediated by the histone methyltransferase inhibitor GSK343 in primary resting T cells is slow, occurring over 96 h, but by itself does not result in a significant upregulation of cell-associated HIV RNA expression or viral antigen production."7.81H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells. ( Archin, NM; Burch, BD; Margolis, DM; McManamy, ME; Tripathy, MK, 2015)
"Demethylation of H3K27 mediated by the histone methyltransferase inhibitor GSK343 in primary resting T cells is slow, occurring over 96 h, but by itself does not result in a significant upregulation of cell-associated HIV RNA expression or viral antigen production."3.81H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells. ( Archin, NM; Burch, BD; Margolis, DM; McManamy, ME; Tripathy, MK, 2015)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tripathy, MK1
McManamy, ME1
Burch, BD1
Archin, NM1
Margolis, DM2
White, CH1
Johnston, HE1
Moesker, B1
Manousopoulou, A1
Richman, DD1
Spina, CA1
Garbis, SD1
Woelk, CH1
Beliakova-Bethell, N1
Ke, R1
Lewin, SR1
Elliott, JH1
Perelson, AS1
Contreras, X1
Schweneker, M1
Chen, CS1
McCune, JM1
Deeks, SG1
Martin, J1
Peterlin, BM1
Friedrich, MJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Research In Viral Eradication of HIV Reservoirs[NCT02336074]Phase 260 participants (Actual)Interventional2015-11-27Completed
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]Phase 16 participants (Actual)Interventional2016-03-31Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Histone H4 Acetylation

Histone H4 acetylation using a H4K5/8/12/16 immunoassay with thawed PBMC derived cell lysates added to an ELISA using anti-H4 monoclonal antibody (NCT02336074)
Timeframe: 12 weeks

InterventionFold increase pre to post vorinostat (Mean)
Intervention (Arm B - ART + Vaccines + Vorinostat)3.19

Quantitative Viral Outgrowth

Number of Participants with undetectable quantitative viral outgrowth (NCT02336074)
Timeframe: At week 16

InterventionParticipants with undetectable outgrowth (Number)
Control (Arm A - ART Only)12
Intervention (Arm B - ART + Vaccines + Vorinostat)6

Total HIV DNA From CD4 T-cells

The average of two measures taken at post-randomisation week 16 and 18 (NCT02336074)
Timeframe: Averaged across post-randomisation week 16 and 18

InterventionHIV-DNA copies/mill CD4+ T cells (log10) (Mean)
Control (Arm A - ART Only)2.95
Intervention (Arm B - ART + Vaccines + Vorinostat)3.06

Viral Inhibition

"CD8+ T cell antiviral suppressive activity was expressed as percentage elimination and determined as follows: [(fraction of p24+ cells in CD4+ T cells cultured alone) - (fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.~Viral inhibition Assay" (NCT02336074)
Timeframe: 12 weeks

InterventionPercentage elimination (Mean)
Control (Arm A - ART Only)-18.25
Intervention (Arm B - ART + Vaccines + Vorinostat)1.50

CD8+ T-cell Responses

Percentage of CD8+ CD107a+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

,
Intervention% cells CD8+ CD107a+ IFNγ+ (Median)
Post randomisation week 9Post randomisation week 12
Control (Arm A - ART Only)0.0520.062
Intervention (Arm B - ART + Vaccines + Vorinostat)0.1940.263

Percentage of CD4+ CD154+ IFNγ+ T Cells

Percentage of CD4+ CD154+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

,
Intervention% cells CD4+ CD154+ IFNγ+ (Median)
Post randomisation week 9Post randomisation week 12
Control (Arm A - ART Only)0.0060.006
Intervention (Arm B - ART + Vaccines + Vorinostat)0.0970.109

Other Studies

5 other studies available for vorinostat and HIV

ArticleYear
H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
    Journal of virology, 2015, Volume: 89, Issue:16

    Topics: Analysis of Variance; CD4-Positive T-Lymphocytes; Chromatin Immunoprecipitation; Enhancer of Zeste H

2015
Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency.
    Antiviral research, 2015, Volume: 123

    Topics: CD4-Positive T-Lymphocytes; Cells, Cultured; Chromatography, Liquid; Gene Expression Profiling; HIV;

2015
Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.
    PLoS pathogens, 2015, Volume: 11, Issue:10

    Topics: Histone Deacetylase Inhibitors; HIV; Humans; Hydroxamic Acids; Transcriptional Activation; Virus Lat

2015
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
    The Journal of biological chemistry, 2009, Mar-13, Volume: 284, Issue:11

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids;

2009
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
    The Journal of biological chemistry, 2009, Mar-13, Volume: 284, Issue:11

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids;

2009
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
    The Journal of biological chemistry, 2009, Mar-13, Volume: 284, Issue:11

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids;

2009
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
    The Journal of biological chemistry, 2009, Mar-13, Volume: 284, Issue:11

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids;

2009
Scientists investigate routing latent HIV from its reservoirs to achieve a cure.
    JAMA, 2012, Jul-25, Volume: 308, Issue:4

    Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Histone Deacetylase In

2012